tiprankstipranks
Trending News
More News >
Curis Inc (CRIS)
NASDAQ:CRIS
US Market
Advertisement

Curis (CRIS) Earnings Dates, Call Summary & Reports

Compare
1,475 Followers

Earnings Data

Report Date
Nov 12, 2025
Before Open (Confirmed)
Period Ending
2025 (Q3)
Consensus EPS Forecast
-0.58
Last Year’s EPS
-1.7
Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings

Earnings Call Summary

Q2 2025
Earnings Call Date:Aug 05, 2025|
% Change Since: 9.58%|
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical trials, particularly in the TakeAim Lymphoma study and promising data in AML and MDS. Financial management has been effective in reducing losses and extending the cash runway. However, challenges in patient enrollment for ultra-rare populations and limited cash reserves pose potential hurdles.
Company Guidance -
Q3 2025
During the Curis Second Quarter 2025 Business Update Call, several key metrics and guidance details were provided. Curis plans to enroll 30 to 40 additional patients over the next 12 to 18 months for their TakeAim Lymphoma study, which adds emavusertib to a patient's BTKi regimen, potentially supporting accelerated submissions in the U.S. and Europe. They aim to initiate a proof-of-concept study in 20 to 30 patients with relapsed/refractory CLL by the end of 2025, with initial data expected by mid-2026. Financially, Curis reported a net loss of $8.6 million or $0.68 per share for Q2 2025, compared to $11.8 million or $2.03 per share in Q2 2024. Research and development expenses decreased to $7.5 million from $10.3 million year-over-year, while cash and cash equivalents stood at $10.1 million as of June 30, 2025, after raising approximately $6 million in July. Curis anticipates funding its operations into Q1 2026 with existing resources and recent offerings.
Progress in TakeAim Lymphoma Study
The TakeAim Lymphoma study, evaluating emavusertib in combination with ibrutinib, is progressing well with collaborative discussions with the FDA and EMA. The study aims for accelerated submissions in the U.S. and Europe with plans to enroll 30 to 40 additional patients.
Positive Data in AML and MDS
Emavusertib showed a 38% composite CR rate in AML with FLT3 mutation, compared to 21% for gilteritinib. The drug's novel mechanism of action is promising for further studies, including a registrational study in AML and a combination study in high-risk MDS.
Productive Financial Management
Net loss decreased to $8.6 million from $11.8 million year-over-year, and research and development expenses decreased significantly, contributing to a cash runway extending into the first quarter of 2026.

Curis (CRIS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

CRIS Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Nov 12, 2025
2025 (Q3)
-0.58 / -
-1.7
Aug 05, 2025
2025 (Q2)
-1.36 / -0.68
-2.0366.50% (+1.35)
May 06, 2025
2025 (Q1)
- / 1.25
-2.05160.98% (+3.30)
Mar 31, 2025
2024 (Q4)
-1.11 / -1.25
-2.0539.02% (+0.80)
Nov 14, 2024
2024 (Q3)
-1.83 / -1.70
-2.1320.19% (+0.43)
Aug 01, 2024
2024 (Q2)
-1.79 / -2.03
-2.415.42% (+0.37)
May 07, 2024
2024 (Q1)
-2.04 / -2.05
-2.414.58% (+0.35)
Feb 08, 2024
2023 (Q4)
-2.12 / -2.03
-2.415.42% (+0.37)
Nov 02, 2023
2023 (Q3)
-2.33 / -2.13
-2.823.93% (+0.67)
Aug 03, 2023
2023 (Q2)
-2.36 / -2.40
-3.429.41% (+1.00)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

CRIS Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Aug 05, 2025
$1.60$1.67+4.37%
May 06, 2025
$2.45$2.19-10.61%
Mar 31, 2025
$2.32$2.10-9.48%
Nov 14, 2024
$3.93$3.98+1.27%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Curis Inc (CRIS) report earnings?
Curis Inc (CRIS) is schdueled to report earning on Nov 12, 2025, Before Open (Confirmed).
    What is Curis Inc (CRIS) earnings time?
    Curis Inc (CRIS) earnings time is at Nov 12, 2025, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is CRIS EPS forecast?
          CRIS EPS forecast for the fiscal quarter 2025 (Q3) is -0.58.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis